295 related articles for article (PubMed ID: 15720571)
1. Study of anticandidal activity of carvacrol and eugenol in vitro and in vivo.
Chami N; Bennis S; Chami F; Aboussekhra A; Remmal A
Oral Microbiol Immunol; 2005 Apr; 20(2):106-11. PubMed ID: 15720571
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of carvacrol and eugenol as prophylaxis and treatment of vaginal candidiasis in an immunosuppressed rat model.
Chami F; Chami N; Bennis S; Trouillas J; Remmal A
J Antimicrob Chemother; 2004 Nov; 54(5):909-14. PubMed ID: 15456732
[TBL] [Abstract][Full Text] [Related]
3. Antifungal treatment with carvacrol and eugenol of oral candidiasis in immunosuppressed rats.
Chami N; Chami F; Bennis S; Trouillas J; Remmal A
Braz J Infect Dis; 2004 Jun; 8(3):217-26. PubMed ID: 15476054
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats.
Martinez A; Ferrer S; Santos I; Jimenez E; Sparrowe J; Regadera J; De Las Heras FG; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Dec; 45(12):3304-9. PubMed ID: 11709301
[TBL] [Abstract][Full Text] [Related]
5. Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats.
Martinez A; Regadera J; Jimenez E; Santos I; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Apr; 45(4):1008-13. PubMed ID: 11257009
[TBL] [Abstract][Full Text] [Related]
6. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
Garg A; Singh S
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activity of Melaleuca alternifolia mixed with tissue conditioner on Candida albicans.
Catalán A; Pacheco JG; Martínez A; Mondaca MA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Mar; 105(3):327-32. PubMed ID: 18280967
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of in vitro activity of carvacrol against Candida albicans strains.
Vardar-Unlu G; Yağmuroğlu A; Unlu M
Nat Prod Res; 2010 Jul; 24(12):1189-93. PubMed ID: 20582812
[TBL] [Abstract][Full Text] [Related]
9. Surface alteration of Saccharomyces cerevisiae induced by thymol and eugenol.
Bennis S; Chami F; Chami N; Bouchikhi T; Remmal A
Lett Appl Microbiol; 2004; 38(6):454-8. PubMed ID: 15130138
[TBL] [Abstract][Full Text] [Related]
10. Eugenol and thymol, alone or in combination, induce morphological alterations in the envelope of Candida albicans.
Braga PC; Sasso MD; Culici M; Alfieri M
Fitoterapia; 2007 Sep; 78(6):396-400. PubMed ID: 17590533
[TBL] [Abstract][Full Text] [Related]
11. Nystatin nanosizing enhances in vitro and in vivo antifungal activity against Candida albicans.
Melkoumov A; Goupil M; Louhichi F; Raymond M; de Repentigny L; Leclair G
J Antimicrob Chemother; 2013 Sep; 68(9):2099-105. PubMed ID: 23620465
[TBL] [Abstract][Full Text] [Related]
12. The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus.
Willis AM; Coulter WA; Fulton CR; Hayes JR; Bell PM; Lamey PJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Mar; 91(3):317-21. PubMed ID: 11250629
[TBL] [Abstract][Full Text] [Related]
13. An ex-vivo oral mucosa infection model for the evaluation of the topical activity of antifungal agents.
Ohnemus U; Willers C; Bubenheim M; Horstkotte MA; Houdek P; Fischer F; Schmage P; Moll I; Brandner JM
Mycoses; 2008 Jan; 51(1):21-9. PubMed ID: 18076591
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effects of carvacrol, nystatin, and their combination on oral candidiasis isolates.
Balef SSH; Hosseini SS; Asgari N; Sohrabi A; Mortazavi N
BMC Res Notes; 2024 Apr; 17(1):104. PubMed ID: 38605312
[TBL] [Abstract][Full Text] [Related]
15. Carvacrol and eugenol differentially stimulate intracellular Ca2+ mobilization and mitogen-activated protein kinases in Jurkat T-cells and monocytic THP-1 cells.
Chan AS; Pang H; Yip EC; Tam YK; Wong YH
Planta Med; 2005 Jul; 71(7):634-9. PubMed ID: 16041649
[TBL] [Abstract][Full Text] [Related]
16. [Sensitivity of Candida strains to polyenic antibiotics in the treatment of oral candidiasis].
Boĭko GI; Sosnin GP; Adarchenko AA; Moroz GS
Antibiotiki; 1984 Nov; 29(11):869-72. PubMed ID: 6395795
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Candida albicans morphogenesis by tumor necrosis factor-alpha and potential for treatment of oral candidiasis.
Ohta H; Tanimoto T; Taniai M; Taniguchi M; Ariyasu T; Arai S; Ohta T; Fukuda S
In Vivo; 2007; 21(1):25-32. PubMed ID: 17354610
[TBL] [Abstract][Full Text] [Related]
18. In vitro effectiveness of mouthrinses against Candida albicans.
Nakamoto K; Tamamoto M; Hamada T
Int J Prosthodont; 1995; 8(5):486-9. PubMed ID: 8595107
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.
Cassone A; De Bernardis F; Torosantucci A; Tacconelli E; Tumbarello M; Cauda R
J Infect Dis; 1999 Aug; 180(2):448-53. PubMed ID: 10395861
[TBL] [Abstract][Full Text] [Related]
20. Fluconazole and/or hexetidine for management of oral candidiasis associated with denture-induced stomatitis.
Koray M; Ak G; Kurklu E; Issever H; Tanyeri H; Kulekci G; Guc U
Oral Dis; 2005 Sep; 11(5):309-13. PubMed ID: 16120118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
